Cellectis (CLLS) Common Equity (2014 - 2026)

Cellectis' Common Equity history runs 13 years deep, the most recent figure standing at $59.9 million for Q1 2026.

• In Q1 2026, Common Equity fell 48.44% year-over-year to $59.9 million; the TTM figure through Mar 2026 stood at $59.9 million (down 48.44% YoY), while the FY2025 annual figure was $75.9 million, down 42.07% from the prior year.
• Common Equity for Q1 2026 stood at $59.9 million, down from $75.9 million in the prior quarter.
• The five-year high for Common Equity was $191.0 million in Q1 2022, with the low at $59.9 million in Q1 2026.
• The 5-year median for Common Equity is $113.7 million (2023), against an average of $115.0 million.
• The sharpest annual moves came in 2024 and 2026: Common Equity soared 70.02% in 2024, then slumped 48.44% in 2026.
• Cellectis' Common Equity stood at $125.9 million in 2022, then slumped by 32.75% to $84.7 million in 2023, then jumped by 54.71% to $131.0 million in 2024, then tumbled by 42.07% to $75.9 million in 2025, then dropped by 21.06% to $59.9 million in 2026.
• Business Quant data shows CLLS's Common Equity at $59.9 million in Q1 2026, $75.9 million in Q4 2025, and $100.5 million in Q3 2025.